Q&A With Hayes Dansky From Janssen: New Research Opens the Door for Xarelto for Atrial Fibrillation Patients

DECEMBER 20, 2015
Adam Hochron
As one of the newest anticoagulants on the market new research has opened the door for more patients to use Xarelto as part of their treatment regimen over the years.

Hayes Dansky, MD, from Janssen Pharmaceuticals discussed how a recent study showed the benefits of taking the medication for patients with nonvalvular atrial fibrillation during the American Heart Association's annual scientfic sessions in Orlando. The medication has been shown to help prevent strokes in these patients and also showed positive results for major bleeding.

Related Coverage >>>
Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.